Adimmune Corporation Sustainability Profile
Adimmune Corporation, a leading biopharmaceutical company based in Taiwan (TW), has been at the forefront of vaccine development since its establishment in 1965. With a strong focus on the research, production, and distribution of vaccines, Adimmune has made significant strides in enhancing public health both locally and internationally. The company is renowned for its innovative vaccine solutions, including those for influenza and other infectious diseases, which are distinguished by their high efficacy and safety profiles. Adimmune's commitment to quality and research excellence has positioned it as a key player in the global vaccine market. Over the years, Adimmune has achieved numerous milestones, solidifying its reputation as a trusted provider of vaccines. Its strategic operations extend beyond Taiwan, reaching various regions, thereby contributing to global health initiatives and responding to emerging health challenges.
DitchCarbon Score
How does Adimmune Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Adimmune Corporation's score of 21 is lower than 82% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Adimmune Corporation's reported carbon emissions
In 2023, Adimmune Corporation, headquartered in Taiwan (TW), reported total carbon emissions of approximately 16,779,000 kg CO2e. This total comprises 4,556,000 kg CO2e from Scope 1 emissions and 12,223,000 kg CO2e from Scope 2 emissions. Notably, there is no reported data for Scope 3 emissions. Comparatively, in 2022, the company recorded total emissions of approximately 16,395,000 kg CO2e, with Scope 1 emissions at 4,572,000 kg CO2e and Scope 2 emissions at 11,823,000 kg CO2e. This indicates a slight increase in total emissions year-on-year. Adimmune Corporation has not disclosed any specific reduction targets or initiatives as part of its climate commitments. The absence of SBTi (Science Based Targets initiative) reduction targets suggests that the company has not yet formalised a strategy for significant emissions reductions in line with global climate goals. Overall, while Adimmune Corporation has made strides in tracking its emissions, further commitments and reduction strategies will be essential for aligning with industry standards and addressing climate change effectively.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 3,215,000 | 0,000,000 | 0,000,000 |
| Scope 2 | 9,265,000 | 00,000,000 | 00,000,000 |
| Scope 3 | - | - | - |
How Carbon Intensive is Adimmune Corporation's Industry?
How Carbon Intensive is Adimmune Corporation's Location?
Adimmune Corporation's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adimmune Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
Kitasato Daiichi Sankyo Vaccine Co., Ltd.
Let us know if this data was useful to you
Usage Policy
You're welcome to quote or reference data from this page, but please include a visible link back to this URL.
Bulk collection, resale, or redistribution of data from multiple profiles is not permitted.
See our License Agreement for more details.